Articles and blog posts on drug development

At RISE we explore how the Safe and Sustainable by Design (SSbD) framework can help reshape safety assessment practices in pharmaceuticals and medical devices from early design all the way to their disposal.

Drug development is at the heart of society. But developing a commercial product is a long, expensive and complex process – and smaller companies can easily get stuck along the way. "With a long-term development partner, you are more likely to secure everything from funding to expertise and equipment," says Anna Minidis, who works with life sciences at RISE.

The life sciences industry aims to improve human health. At the same time, the sector is responsible for a significant climate impact. And the transition faces particular challenges. "We in the research community can help to better understand what can be changed and provide relevant assessment methods and tools. This will help focus efforts where they are needed and where they will be most effective," says Björn Gregertsen at RISE.

The Swiss biotech company Juvabis is developing a new substance, EBL-1003, as part of the ENABLE project. The substance could be used to treat patients with illnesses caused by multi-resistant bacteria.

When a drug is going to be developed, not only does an active substance have to be developed - it must also be an effective drug preparation, so that the substance can be properly absorbed by the body. RISE is collaborating with the pharmaceutical company Umecrine Cognition, which is developing an effective new drug, which can help patients who have hitherto received inadequate treatment.